BioCryst Pharmaceuticals, Inc.
BCRX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $2 | $2 | $2 | $2 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $1 | $1 | $1 |
| Enterprise Value | $2 | $3 | $2 | $2 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -2.4% | 12.2% | 10.6% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 98.4% | 98.3% | 96.9% | 95.3% |
| EBITDA | $0 | $0 | $0 | -$0 |
| % Margin | 20.2% | 17.4% | 16.9% | -0.9% |
| Net Income | $0 | $0 | $0 | -$0 |
| % Margin | 8.1% | 3.1% | 0% | -20.4% |
| EPS Diluted | 0.059 | 0.02 | 0 | -0.13 |
| % Growth | 193.5% | – | 100% | – |
| Operating Cash Flow | $0 | $0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | $0 | $0 | -$0 | -$0 |